The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

NEW YORK – Immunotherapy developer Xilio Therapeutics will showcase new masked T-cell engagers in its clinical pipeline over the next two years, the company said this week while announcing second ...

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.